Many patients with chronic kidney disease (CKD) receive anticoagulation or antiplatelet
therapy due to atrial fibrillation, coronary artery disease, thromboembolic disease, or …

Background: Both atrial fibrillation and venous thromboembolism (VTE) are highly prevalent
among patients with chronic kidney disease (CKD). Until recently, warfarin was the most …

It is unclear whether warfarin is protective or harmful in patients with ESRD and atrial
fibrillation. This state of equipoise raises the question of whether alternative anticoagulants …

Background Direct‐acting oral anticoagulants (DOAC s) are used in patients with splanchnic
vein thrombosis (SVT) and cirrhosis, but evidence for safety and efficacy in this setting is …

The article reviews the diagnosis of acute coronary syndromes in dialysis patients, current
literature on myocardial revascularization, and data on fatal and nonfatal cardiac arrhythmia …

The direct oral anticoagulants (DOACs) are drugs used in clinical practice since 2009 for the
prevention of stroke or systemic embolism in non-valvular atrial fibrillation, and for the …

In recent years, small oral compounds that specifically block activated coagulation factor X
(FXa) or thrombin (FIIa) have become alternatives to the anticoagulants that had been used …

Abstract Use of Direct Oral Anticoagulants (DOACs) is continuously increasing for clinical
application. The first product released was Dabigatran, which was proposed for many …

Background: Approximately 3% of Tuberculosis (TB) patients have a venous
thromboembolic events (VTE). The use of Vitamin K antagonists (VKAs), as anticoagulant, in …

Purpose Oral anticoagulants (AC) and antiplatelet (AP) agents are increasingly prescribed
to prevent and treat acute and chronic thrombotic conditions. The direct oral anticoagulants …